International Journal of Leading Research Publication
E-ISSN: 2582-8010
•
Impact Factor: 9.56
A Widely Indexed Open Access Peer Reviewed Multidisciplinary Monthly Scholarly International Journal
Plagiarism is checked by the leading plagiarism checker
Call for Paper
Volume 7 Issue 11
November 2026
Indexing Partners
In silico identification of potential dopamine D2 receptor antagonists from Rauwolfia serpentina phytoconstituents.
| Author(s) | Mr. Souvik Chakraborty, Ms. Sushmita Bhowmick, Dr. Sajal Dey, Dr. Tarasankar Maiti |
|---|---|
| Country | India |
| Abstract | Schizophrenia (Scz) is a complex neuropsychiatric disorder with a spectrum of symptoms that are broadly classified into two main categories, namely, the positive and negative symptoms. Positive symptoms of Scz, such as hallucinations and delusions, are associated with the excessive activation of dopamine D2 receptors, leading to dysregulated dopamine neurotransmission. D2 receptor antagonism remains one of the central therapeutic strategies for controlling positive symptoms of Scz. In the present study, 39 phytoconstituents were identified in Rauwolfia serpentina using Indian Medicinal Plants, Phytoconstituents and Therapeutics (IMPPAT). 39 phytoconstituents were then docked against the 3D-modeled protein structure of the dopamine D2 receptor to assess the binding affinity of the phytoconstituents with the protein structure. Molecular docking identified that 11 compounds had binding energy less than -9kcal/mol. The assessment of absorption, distribution, metabolism, excretion, and toxicity (ADMET) was done for the 11 compounds, and only 4 phytoconstituents passed the ADMET filters, namely yohimbine, 1,2-dihydrovomilenine, corynanthine, and Rauwolscine. Due to the known toxicity profiles of yohimbine, Rauwolscine, and Corynanthine, only 1,2-dihydrovomilenine is chosen for further studies. The docked complex of the D2 receptor and 1,2-dihydrovomilenine is further studied for stability using normal mode analysis, which showed that the complex remains stable. These findings suggest that 1,2-dihydrovomilenine can be used for further in vitro and in vivo-based studies for further investigation and that it possesses all the necessary requirements to act as a potential D2 receptor antagonist. |
| Keywords | Schizophrenia, Molecular docking, ADMET, dopamine receptor |
| Field | Medical / Pharmacy |
| Published In | Volume 7, Issue 11, November 2026 |
| Published On | 2026-11-04 |
| DOI | https://doi.org/10.70528/IJLRP.v7.i11.2476 |
Share this

IJLRP's Crossref DOI prefix is
10.70528/IJLRP
Downloads
All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.